MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Rhea-AI Summary
MIRA Pharmaceuticals (NASDAQ:MIRA) executed an Amended and Restated Exclusive License Agreement with MIRALOGX, granting worldwide exclusive rights to MIRA-55 and SKNY-1.
The deal consolidates global development, commercialization, sublicensing, and IP enforcement across MIRA’s pipeline, including Ketamir-2, without materially changing core economic terms.
Positive
- Worldwide exclusive rights to MIRA-55 and SKNY-1 secured
- Unified global rights structure across core assets Ketamir-2, MIRA-55, SKNY-1
- Expanded sublicensing and IP enforcement rights for future partnerships
- Amendment does not materially change previously disclosed core economic terms
Negative
- None.
News Market Reaction – MIRA
In the Jun 4 session, MIRA gained 4.95%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.6% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Global IP expansion | Positive | +18.6% | Expanded Ketamir-2 license to worldwide rights across major markets. |
| May 14 | Phase 1 data | Positive | +0.4% | Positive unblinded Phase 1 Ketamir-2 results in 57 volunteers with good safety. |
| May 13 | Preclinical publication | Positive | -4.8% | Peer-reviewed SKNY-1 zebrafish obesity/nicotine data with ~30% weight loss. |
| Mar 23 | Preclinical safety data | Positive | +22.3% | Mira-55 showed morphine-like analgesia without THC or rimonabant CNS side effects. |
| Mar 04 | Trial completion | Positive | -1.6% | Completed Phase 1 dosing of Ketamir-2 with no serious adverse events reported. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive R&D and IP updates have often led to upside, but there are instances where favorable data or publications saw negative or muted price reactions.
Over recent months, MIRA has consistently advanced its pipeline and IP position. On Mar 23, Mira-55 preclinical safety data preceded a 22.28% gain. Subsequent SKNY-1 manuscript news on May 13 saw a -4.8% move despite positive obesity/addiction data. Ketamir-2 Phase 1 milestones and expanded global rights on May 27 drove moves of 18.58% and modest gains. Today’s global rights consolidation for MIRA-55 and SKNY-1 extends this strategy of tightening control over core assets.
Key Terms
exclusive license agreement financial
sublicensing rights financial
intellectual property technical
IND filings regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities
MIAMI, FL / ACCESS Newswire / June 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to MIRA-55 and SKNY-1.
The amended agreement grants MIRA worldwide exclusive development, commercialization, sublicensing, and intellectual property enforcement rights relating to both programs. The transaction further consolidates the Company's intellectual property portfolio and establishes a unified global rights structure across MIRA's core therapeutic assets.
MIRA-55 is the Company's proprietary oral investigational drug candidate being developed for chronic inflammatory pain. SKNY-1 is MIRA's oral investigational drug candidate being developed for obesity and addiction-related disorders.
Under the terms of the amended agreement, MIRA receives worldwide exclusive rights under jointly owned intellectual property covering MIRA-55, as well as worldwide exclusive rights covering SKNY-1. The agreement also provides MIRA with worldwide sublicensing rights and enhanced intellectual property enforcement rights, strengthening the Company's ability to pursue future licensing, co-development, and commercialization opportunities.
The amendment does not materially modify the previously disclosed core economic terms of the existing license arrangements.
Erez Aminov, Chairman and CEO of MIRA Pharmaceuticals, stated:
"With this agreement, MIRA now controls global development and commercialization rights across its entire pipeline - Ketamir-2, MIRA-55, and SKNY-1. As we advance Ketamir-2 into Phase 2a and move both MIRA-55 and SKNY-1 toward IND filings, having a clean, unified worldwide rights structure in place is exactly where we need to be. It strengthens our position with partners, with investors, and across every market we intend to operate in."
Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals, commented:
"MIRA-55 and SKNY-1 each address large patient populations with significant unmet need. What sets these programs apart is their differentiated approach - targeting pathways that existing therapies either miss or handle poorly. Securing worldwide exclusive rights ensures we control how these assets are developed and ultimately reach patients."
About MIRA-55
MIRA-55 is a next-generation cannabinoid analog designed to modulate cannabinoid receptor activity, including CB1 and CB2 pathways, while minimizing CB1-related psychoactive activity. In preclinical inflammatory pain models, MIRA-55 demonstrated analgesic activity comparable to injected morphine in normalizing pain responses, supporting its continued development as a potential non-opioid therapeutic. The U.S. Drug Enforcement Administration (DEA) has confirmed, following scientific review, that MIRA-55 is not classified as a controlled substance. MIRA-55 is an investigational compound and has not been approved by the FDA or any regulatory authority.
About SKNY-1
SKNY-1 is an orally administered investigational drug candidate designed to modulate multiple pathways associated with metabolic regulation and reward-associated behaviors. The compound was designed to combine pathway-selective CB1 modulation, CB2 receptor activity, and selective MAO-B inhibition. In preclinical studies, oral administration of SKNY-1 was associated with dose-dependent reductions in body weight and lipid normalization, with no significant reduction in whole-body density observed during the treatment period - a finding relevant in the context of ongoing clinical focus on lean body mass preservation during weight reduction. SKNY-1 has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority, and its safety and efficacy have not been established in humans.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of investigational therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates being evaluated for neuropathic pain (CIPN), inflammatory pain, obesity, addiction-related disorders, anxiety, and cognitive impairment. For more information, please visit www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "can," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential," "intend," "seek," "target" and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of MIRA-55, SKNY-1, and the Company's other product candidates. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management's beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K and the Company's other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the "Investors" section of our website at MIRA Investors, for a discussion of these and other risks and uncertainties.
Contact:
Krystina Quintana
info@mirapharma.com
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original press release on ACCESS Newswire